Barclays lowered the firm’s price target on Vir Biotechnology to $27 from $41 and keeps an Overweight rating on the shares following quarterly results. Vir highlighted key data update for VIR-2218/VIR-3434 in HBV/HDV at AASLD, the firm pointed out in a research note on Friday. With multiple early stage candidates and strong cash position, Barclays sees long-term upside potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VIR:
- Vir Biotechnology files automatic mixed securities shelf
- Vir Biotechnology reports Q3 EPS ($1.22), consensus ($1.21)
- Vir Biotechnology appoints Jennifer Towne, Ph.D., as Chief Scientific Officer
- Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
- Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
